Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression

23 Nov 2022

Abstract excerpt

Abstract MEK inhibitors (MEKi) have limited efficacy in KRAS mutant lung adenocarcinoma (LUAD) patients, and this is attributed to both intrinsic and adaptive mechanisms of drug resistance. While many studies have focused on the former, there remains a dearth of data regarding acquired resistance to MEKi in LUAD. We established trametinib-resistant KRAS mutant LUAD cells through dose escalation and performed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Treatments and Mutations
Share to Melanoma and MAPK Pathways
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36418460
DOI: 10.1038/s41698-022-00328-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppressionPMID 36418460Read ↗

MEK inhibitor resistance in lung cancer cells associated with addiction to sustained ERK suppressionSemantic proximity Read ↗

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies.Semantic proximity Read ↗

Cancer therapy based on oncogene addictionSemantic proximity Read ↗

MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated.Semantic proximity Read ↗

Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.Semantic proximity Read ↗

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancerSemantic proximity Read ↗

A combinatorial strategy for treating KRAS-mutant lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in lung cancer.Semantic proximity Read ↗

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.Semantic proximity Read ↗

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant CancersSemantic proximity Read ↗

A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer.Semantic proximity Read ↗

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.